Opko Health (OPK) closed at $1.61 on November 19, 2026, down 4.7% from the previous close, on volume of 2,051,930 shares (30-day average 5,025,092).
Data as of November 19, 2026.
19-Nov-2026
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Mon, 16-Nov 8:30 AM ET)
Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results
Globe Newswire (Sun, 15-Nov 7:00 AM ET)
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
Globe Newswire (Wed, 4-Nov 4:23 PM ET)
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026
Globe Newswire (Wed, 28-Oct 8:52 AM ET)
Globe Newswire (Tue, 27-Oct 8:00 AM ET)
Market Chameleon (Thu, 15-Oct 6:25 AM ET)
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
PRNewswire (Thu, 15-Oct 7:30 AM ET)
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
Globe Newswire (Tue, 8-Sep 1:55 PM ET)
OPKO Health Narrows Losses and Advances Pipeline in Q2 2026 Amid Key Program Milestones
Market Chameleon (Tue, 28-Jul 6:29 AM ET)
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Opko Health trades on the NASDAQ stock market under the symbol OPK.
As of November 19, 2026, OPK stock price declined to $1.61 with 2,051,930 million shares trading.
OPK has a beta of 0.21, meaning it tends to be less sensitive to market movements. OPK has a correlation of 0.00 to the broad based SPY ETF.
OPK has a market cap of $1.20 billion. This is considered a Small Cap stock.
Last quarter Opko Health reported $65 million in Revenue and -$.05 earnings per share. This fell short of revenue expectation by $-71 million and exceeded earnings estimates by $.01.
In the last 3 years, OPK traded as high as $2.04 and as low as $.85.
The top ETF exchange traded funds that OPK belongs to (by Net Assets): IWM, VTI, VB, VXF, IWN.
OPK has outperformed the market in the last year with a return of +25.8%, while the SPY ETF gained +9.6%. In the last 3 month period, OPK beat the market returning +18.4%, while SPY returned -6.5%. However, in the most recent 2 weeks OPK has underperformed the stock market by returning -9.0%, while SPY returned -6.6%.
OPK support price is $1.64 and resistance is $1.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OPK shares will trade within this expected range on the day.